Mei Pei-Yuan, Xiao Han, Guo Qiang, Meng Wang-Yang, Wang Ming-Liang, Huang Quan-Fu, Liao Yong-De
Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Oncol Lett. 2022 Dec 27;25(2):68. doi: 10.3892/ol.2022.13654. eCollection 2023 Feb.
Esophageal cancer (ESCA) is a lethal malignancy and is associated with the alterations of various genes and epigenetic modifications. The protein dpy-30 homolog (DPY30) is a core member of histone H3K4 methylation catalase and its dysfunction is associated with the occurrence and development of cancer. Therefore, the present study investigated the role of DPY30 in ESCA and evaluated the association between the expression of DPY30, the clinicopathological characteristics of ESCA and the tumor immune microenvironment. It conducted a comprehensive analysis of DPY30 in patients with ESCA using The Cancer Genome Atlas (TCGA) database and clinical tissue microarray specimens of ESCA. Immunohistochemistry was performed to assess the expression levels of DPY30 in tissues. Receiver operating curve analysis, Kaplan-Meier survival analysis and Cox regression analysis were performed to identify the diagnostic and prognostic value of DPY30. Gene Set Enrichment Analysis, protein-protein interaction network and Estimation of Stromal and Immune cells in Malignant Tumor tissues using the Expression data were used to screen DPY30-associated genes and evaluate the immune score of the TCGA samples. The results demonstrated that the expression of mRNA and protein levels of DPY30 were significantly upregulated in tumor tissues compared with normal tissue samples. The expression of DPY30 was closely associated with the poor prognosis of patients with ESCA. The present study also found that DPY30 expression and the pathological characteristics of ESCA were significantly correlated. Additionally, the expression of DPY30 demonstrated a significant positive correlation with various immune cells infiltration. The results suggested that DPY30 might influence tumor immune infiltration. In conclusion, the findings suggested that DPY30 might be a potential prognostic biomarker and an immunotherapeutic target in ESCA.
食管癌（ESCA）是一种致命的恶性肿瘤，与多种基因改变和表观遗传修饰有关。蛋白质dpy - 30同源物（DPY30）是组蛋白H3K4甲基化催化酶的核心成员，其功能障碍与癌症的发生发展相关。因此，本研究探讨了DPY30在食管癌中的作用，并评估了DPY30表达、食管癌临床病理特征与肿瘤免疫微环境之间的关联。利用癌症基因组图谱（TCGA）数据库和食管癌临床组织芯片标本，对食管癌患者的DPY30进行了综合分析。采用免疫组织化学法评估组织中DPY30的表达水平。进行受试者工作特征曲线分析、Kaplan - Meier生存分析和Cox回归分析，以确定DPY30的诊断和预后价值。使用基因集富集分析、蛋白质 - 蛋白质相互作用网络以及利用表达数据估计恶性肿瘤组织中的基质和免疫细胞，来筛选与DPY30相关的基因并评估TCGA样本的免疫评分。结果表明，与正常组织样本相比，肿瘤组织中DPY30的mRNA和蛋白水平表达显著上调。DPY30的表达与食管癌患者的不良预后密切相关。本研究还发现DPY30表达与食管癌的病理特征显著相关。此外，DPY30的表达与各种免疫细胞浸润呈显著正相关。结果提示DPY30可能影响肿瘤免疫浸润。总之，研究结果表明DPY30可能是食管癌潜在的预后生物标志物和免疫治疗靶点。
